COMP <GO>
PBH vs AUPH // EV/EBITDA & P/E VALUATION
Prestige Consumer Healthcare Inc. (NYSE) VS. Aurinia Pharmaceuticals Inc (NASDAQ) • 15-METRIC TALLY: PBH 4
— AUPH 8
▲ EV/EBITDA & P/E VALUATION LEADER: PBH
LAST: $48.75 (+2.01%) • MKT CAP: $2.31B
valuation
7.0x
LAST: $17.21 (-0.86%) • MKT CAP: $2.29B
valuation
21.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PBH VS. AUPH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PBH | AUPH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.70% | 88.50% | -33.80 | AUPH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.80% | 16.50% | -2.70 | AUPH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 7.0x | 21.1x | -14.10 | PBH | /valuation <GO> |
| Free Cash Flow Yield | 10.67% | 5.92% | +4.75 | PBH | /fcf-yield <GO> |
| Operating Margin | 28.40% | 37.10% | -8.70 | AUPH | /operating-margins <GO> |
| Net Profit Margin | 17.50% | 68.00% | -50.50 | AUPH | /net-margins <GO> |
| Revenue Growth (YoY) | -4.30% | 20.40% | -24.70 | AUPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.21 | 8.33 | -6.12 | AUPH | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | AUPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.1 | 49.5 | +4.66 | PBH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.3x | 6.7x | +4.60 | AUPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.31B | $2.29B | $19.7M | PBH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PBH REV | AUPH REV | PBH GROSS % | AUPH GROSS % | PBH FCF | AUPH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.09B | $283.1M | 54.7% | 88.5% | $246.4M | $135.7M |
| FY 2024 | $1.14B | $235.1M | 55.8% | 88.0% | $243.3M | $44.4M |
| FY 2023 | $1.13B | $175.5M | — | — | $248.9M | -$33.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PBH // BETA —
AUPH // BETA —